Stock A249420 ILDONG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Ildong Pharmaceutical Co., Ltd.

Equities

A249420

KR7249420001

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
15,280 KRW +1.39% Intraday chart for Ildong Pharmaceutical Co., Ltd. +1.73% -15.86%
2023 Il Dong Pharmaceutical Eyes Approval for to Manufacture Japan's COVID-19 Treatment in South Korea MT
2023 Il Dong Pharmaceutical Introduces New R&D Unit Yunovia MT

Valuation

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Capitalization 1 379,499 764,721 502,483 426,807 - -
Enterprise Value (EV) 1 379,542 764,721 502,483 426,807 426,807 426,807
P/E ratio - - - 12.2 x 7.82 x 7.41 x
Yield - - - - - -
Capitalization / Revenue 0.73 x 1.2 x 0.84 x 0.67 x 0.61 x 0.58 x
EV / Revenue 0.73 x 1.2 x 0.84 x 0.67 x 0.61 x 0.58 x
EV / EBITDA 14.7 x -17.8 x - 5.27 x 4.1 x 3.88 x
EV / FCF 13.4 x - - 9.08 x 6.47 x 6.37 x
FCF Yield 7.48% - - 11% 15.5% 15.7%
Price to Book 1.44 x - - 2.1 x 1.66 x 1.35 x
Nbr of stocks (in thousands) 23,790 26,785 27,670 27,932 - -
Reference price 2 15,952 28,550 18,160 15,280 15,280 15,280
Announcement Date 2/14/20 2/9/23 2/8/24 - - -
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Net sales 1 516.8 635.8 597.9 639.7 700 741
EBITDA 1 25.73 -42.98 - 81 104 110
EBIT 1 -1.901 -72.15 -40.91 55.8 80.3 87
Operating Margin -0.37% -11.35% -6.84% 8.72% 11.47% 11.74%
Earnings before Tax (EBT) 1 - - -82.04 39.1 64.6 72
Net income 1 - - -71.49 35.2 54.9 58
Net margin - - -11.96% 5.5% 7.84% 7.83%
EPS 2 - - - 1,255 1,955 2,061
Free Cash Flow 3 28,374 - - 47,000 66,000 67,000
FCF margin 5,490.12% - - 7,347.19% 9,428.57% 9,041.84%
FCF Conversion (EBITDA) 110,256.09% - - 58,024.69% 63,461.54% 60,909.09%
FCF Conversion (Net income) - - - 133,522.73% 120,218.58% 115,517.24%
Dividend per Share - - - - - -
Announcement Date 2/14/20 2/9/23 2/8/24 - - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q2 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 162 149.4 151.4 158.4 164.1 165.8
EBITDA - - - - - -
EBIT 1 -22.03 - 12.9 10.1 14.2 18.6
Operating Margin -13.6% - 8.52% 6.38% 8.65% 11.22%
Earnings before Tax (EBT) 1 - 0.017 12.4 6.2 8.2 12.4
Net income 1 - 7.501 11.1 5.5 7.4 11.2
Net margin - 5.02% 7.33% 3.47% 4.51% 6.76%
EPS - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/27/22 2/8/24 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2022 2023 2024 2025 2026
Net Debt 42.5 - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) 1.65 x - - - - -
Free Cash Flow 1 28,374 - - 47,000 66,000 67,000
ROE (net income / shareholders' equity) -5.13% - - 19.2% 24% 20.3%
ROA (Net income/ Total Assets) -2.31% - - 6.1% 9% 8.7%
Assets 2 - - - 577 610 666.7
Book Value Per Share 3 11,116 - - 7,260 9,216 11,277
Cash Flow per Share 3 - - - 2,164 2,810 2,870
Capex 2 12 - - 15 15 15
Capex / Sales 2.33% - - 2.34% 2.14% 2.02%
Announcement Date 2/14/20 2/9/23 2/8/24 - - -
1KRW in Million2KRW in Billions3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ILDONG PHARMACEUTICAL CO., LTD. Stock Ildong Pharmaceutical Co., Ltd.
-15.86% 310M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A249420 Stock
  4. Financials Ildong Pharmaceutical Co., Ltd.